NCT06521255

Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Randomized, Multi-center, Phase 3 Study of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 244 (estimated)
• Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Randomized, Multi-center, Phase 3 Study of Tafasitamab and Lenalidomide in Combination with Gemcitabine and Oxaliplatin versus Rituximab in Combination with Gemcitabine and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphom

Conditions

• DLBCL

Interventions

Type	Name	Description
DRUG	Tafasitamab	Tafasitmab was infused intravenously
DRUG	Lenalidomide	Lenalidomide orally
DRUG	Gemcitabine	Gemcitabine was infused intravenously
DRUG	Oxaliplatin	Oxaliplatin was infused intravenously
DRUG	Rituximab	Rituximab was infused intravenously.

Timeline

• Start date: 2024-05-07
• Primary completion: 2028-09-01
• Completion: 2029-12-01
• First posted: 2024-07-25
• Last updated: 2024-07-25

Locations

20 sites across 1 country: China